UNCY: Unicycive Therapeutics, Inc. Stock

by  •  • Comments Off on UNCY: Unicycive Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 90.52
Enterprise Value ($M) 70.75
Book Value ($M) 11.27
Book Value / Share 0.09
Price / Book 8.03
NCAV ($M) 10.67
NCAV / Share 0.09
Price / NCAV 8.48

Profitability (mra)
Return on Invested Capital (ROIC) -1.27
Return on Assets (ROA) -0.29
Return on Equity (ROE) -0.70

Liquidity (mrq)
Quick Ratio 1.64
Current Ratio 1.64

Balance Sheet (mrq) ($M)
Current Assets 27.35
Assets 27.95
Liabilities 16.68
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -32.12
Net Income -36.73

Cash Flow Statement (mra) ($M)
Cash From Operations -28.57
Cash from Investing -0.07
Cash from Financing 45.09

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-15 13G/A Vivo Opportunity Fund Holdings, L.P. 9.99 0.00
05-15 13G/A Nantahala Capital Management, LLC 9.99 12.54
05-15 13G/A Ra Capital Management, L.p. 9.90 15.33
02-14 13G/A Great Point Partners Llc 9.99 20.49
02-06 13G/A Walleye Capital LLC 4.82 0.00
12-20 13G/A Nantahala Capital Partners Limited Partnership 2.76 -61.85
11-14 13G/A Logos Global Management LP 4.90 46.37
11-14 13G/A Biotechnology Value Fund L P 9.99 201.74
10-11 13G Octagon Capital Advisors LP 9.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-06 411,551 2,182,468 18.86
2025-06-05 842,036 3,394,589 24.81
2025-06-04 2,041,620 7,974,114 25.60
2025-06-03 3,292,483 12,022,740 27.39
2025-06-02 617,795 2,796,005 22.10

(click for more detail)

Similar Companies
TRAW – Traws Pharma, Inc. TSBX – Turnstone Biologics Corp.
TTNP – Titan Pharmaceuticals, Inc. UPC – Universe Pharmaceuticals INC
UPXI – Upexi, Inc.


Financial data and stock pages provided by
Fintel.io